Boswellia serrata is a tree that grows across India, North Africa, and parts of the Middle East. Its resin has been used in Ayurvedic medicine for centuries to calm inflamed joints and troubled guts. That alone doesn't mean much — plenty of traditional remedies fall apart under scrutiny. But boswellia didn't. When researchers looked at its active compounds, called boswellic acids, they found something with a very specific mechanism. And when they tested it in clinical trials on colitis and Crohn's, the numbers held up.
Boswellia was something I hadn't heard of until I started really digging into the research. Most people haven't. Turmeric gets all the press. But the evidence behind boswellia is solid, and in our practice we've seen it play a genuine role for clients working through gut inflammation.
How Boswellic Acids Actually Work
Here's what happens at the cellular level. Your body produces an enzyme called 5-lipoxygenase, or 5-LOX for short. This enzyme drives the production of leukotrienes — inflammatory molecules that are heavily involved in the mucosal damage you see in ulcerative colitis. In a gut that's functioning well, leukotriene production stays in check. In IBD, that regulation breaks down. Leukotriene levels spike, and the result is swelling, tissue damage, and ulceration along the colon wall.
Boswellic acids — especially one called AKBA (acetyl-11-keto-beta-boswellic acid) — directly block 5-LOX. That matters because it's a different pathway than what most anti-inflammatory drugs target. NSAIDs go after the COX enzymes. Steroids suppress your entire immune response, which is why they come with such a long list of side effects. Boswellia is more selective. It shuts down the leukotriene cascade without broadly hammering the immune system.
There's a second mechanism too. Boswellic acids also inhibit human leukocyte elastase (HLE), an enzyme that white blood cells release during inflammation. HLE chews through connective tissue — it's part of what makes chronic colitis so destructive over time. By blocking HLE, boswellia adds a layer of tissue protection on top of its anti-inflammatory effect. That dual action is what makes this compound interesting.
The Numbers: 70% Remission in a Colitis Trial
One of the first clinical trials on boswellia and colitis enrolled 20 patients with chronic disease who hadn't responded well to standard treatment. They took 900 milligrams of Boswellia serrata resin per day — split into three doses — for six weeks.
Fourteen of those 20 patients, 70%, went into remission. The researchers documented less bleeding, firmer stools, and visible mucosal healing on sigmoidoscopy. Side effects were minimal. Now, compare that to the control group on sulfasalazine, where remission hit around 40%. A small study, yes. Not placebo-controlled. But those numbers are hard to ignore — especially from a plant extract with almost no adverse effects.
That trial opened the door. And the research that followed backed it up.
Crohn's Disease: Head-to-Head with Mesalazine
A larger study took 102 patients with active Crohn's disease and ran a proper double-blind comparison. One group received a standardised boswellia extract called H15, at 3,600 milligrams per day. The other group took mesalazine — one of the most commonly prescribed IBD medications — at 4,500 milligrams per day. The trial lasted eight weeks.
Both groups improved. Disease activity scores dropped comparably in the boswellia group and the mesalazine group. There was no meaningful difference between the two. A plant resin, performing on par with a pharmaceutical that millions of people take daily. The side-effect profiles were similar too.
That's worth sitting with. Not because it means you should swap your medication for frankincense tomorrow — but because it tells you there's more going on with this compound than folklore.
Where Boswellia Fits — and Where It Doesn't
I want to be straightforward about this. Boswellia is not a rescue drug for a severe flare. If you're losing blood and dropping weight, you need your gastroenterologist, not a supplement. We've never positioned it that way in our practice, and the research doesn't support that use.
Where we do see it working is in mild to moderate inflammation, during maintenance phases, and as part of a broader protocol. The selective 5-LOX inhibition means you're calming a specific inflammatory pathway without the fallout that comes with long-term steroid use — the bone loss, the metabolic disruption, the increased infection risk. And the HLE inhibition adds tissue protection that most conventional IBD drugs don't address at all.
In our practice, boswellia is one piece of a bigger picture. It sits alongside dietary changes, gut barrier support, and stress management. That's how recovery works — compound effects, not single bullets.
Practical Notes on Quality and Dosing
If you're considering boswellia, quality matters. Look for standardised extracts that list the AKBA content on the label — AKBA is the most pharmacologically active boswellic acid. If a product doesn't specify that, move on. The clinical trials used dosages ranging from 900 to 3,600 milligrams of total extract per day, always divided into three doses taken with food.
Talk to your doctor before adding it, particularly if you're on immunosuppressants or blood thinners. Interactions haven't been fully mapped out yet. Most people tolerate boswellia well, though some notice mild stomach discomfort or reflux at higher doses.
And one more thing — don't expect overnight results. Like most natural anti-inflammatories, boswellia works gradually. The trial that showed 70% remission ran for six weeks. Recovery from gut inflammation takes time. That's true whether you're using pharmaceuticals, natural compounds, or both.
References
- Gupta, I. et al. — Effects of Boswellia serrata gum resin in patients with chronic colitis. Planta Medica, 2001; 67(5): 391–395.
- Gerhardt, H. et al. — Therapy of active Crohn disease with Boswellia serrata extract H15. Zeitschrift für Gastroenterologie, 2001; 39(1): 11–17.
- Ammon, H.P.T. — Boswellic acids in chronic inflammatory diseases. Planta Medica, 2006; 72(12): 1100–1116.
- Safayhi, H. et al. — Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. Journal of Pharmacology and Experimental Therapeutics, 1992; 261(3): 1143–1146.